Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels

• Katie Stone,

  Affiliation Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Emily Woods,

  Affiliation Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Susann M. Szmania,

  Affiliation Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Owen W. Stephens,

  Affiliation Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Tarun K. Garg,

  Affiliation Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• Bart Barlogie,

  Affiliation Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯
• John D. Shaughnessy Jr,

  Affiliation Signal Genetics, LLC., New York, New York, United States of America

  ⨯
• Brett Hall,

  Affiliation Janssen Research and Development, Radnor, Pennsylvania, United States of America

  ⨯
• Manjula Reddy,

  Affiliation Janssen Research and Development, Radnor, Pennsylvania, United States of America

  ⨯
• Antje Hoering,

  Affiliation Cancer Research and Biostatistics, Seattle, Washington, United States of America

  ⨯
• Emily Hansen,

  Affiliation Cancer Research and Biostatistics, Seattle, Washington, United States of America

  ⨯
• Frits van Rhee

  * E-mail: vanrheefrits@uams.edu

  Affiliation Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

  ⨯